Key facts
- This page summarizes Mark S. Forman's Form 4 filing for Passage BIO, Inc. (PASG).
- 6 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 13 Feb 2024, 19:34.
Mark S. Forman - 16 Aug 2021 Form 4 Insider Report for Passage BIO, Inc. (PASG)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- PASG
- Reported as of
- 16 Aug 2021
- Net transaction value
- -$1,589
- SEC form
- 4
- Accepted by SEC
- 13 Feb 2024, 19:34:59 UTC
- Next SEC filing
- 08 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edgar Cale, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark S. Forman filed Form 4 for Passage BIO, Inc. (PASG) on 13 Feb 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$1,589.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PASG
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,000
- Change %
- +11%
- Price
- Shares after
- 50,269
- Date
- 10 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
PASG
transaction
Common Stock
Sale
- Transaction value
- $1,589
- Shares
- -1,638
- Change %
- -3.3%
- Price
- $0.9700
- Shares after
- 48,631
- Date
- 13 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PASG
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +130,000
- Change %
- Price
- $0.000000
- Shares after
- 130,000
- Date
- 16 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 130,000
- Exercise price
- $10.84
- Footnotes
- F3
PASG
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 10 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $4.52
- Footnotes
- F4
PASG
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 10 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- Footnotes
- F1, F5
PASG
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 10 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Footnote F2
The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
Footnote F3
The stock option vests as to 25% of the total shares on August 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F4
The stock option vests as of 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F5
1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.